Biomind Labs Inc (BMND) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bmnd08, Brain Electrical Activity Monitor, Pharmacokinetic Study Of Sublingually Administered Psychoactive Substance, Biochemical Determinations, Acute Subjective Ratings Of Psychedelic Effects, Vital Signs, Cognitive Assessments, Psychiatric Assessments | Healthy Volunteers | phase1AndPhase2 | Completed | Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety | Dec 10, 2024 | ― |
| Acute Subjective Ratings Of Psychedelic Effects, Vital Signs, Cognitive Assessments, Psychiatric Assessments, Sublingual Administration, Electroencephalography, Biochemical Mesurements | Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder | phase1AndPhase2 | Completed | Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI | Dec 10, 2024 | ― |
| N,N-Dimethyltryptamine | Healthy Volunteers | Phase I | Completed | Clinical Study of DMT in Healthy Adults | Oct 06, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bmnd08, Brain Electrical Activity Monitor, Pharmacokinetic Study Of Sublingually Administered Psychoactive Substance, Biochemical Determinations, Acute Subjective Ratings Of Psychedelic Effects, Vital Signs, Cognitive Assessments, Psychiatric Assessments | phase1AndPhase2 | Healthy Volunteers | Completed | Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety | Dec 10, 2024 | ― |
| Acute Subjective Ratings Of Psychedelic Effects, Vital Signs, Cognitive Assessments, Psychiatric Assessments, Sublingual Administration, Electroencephalography, Biochemical Mesurements | phase1AndPhase2 | Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder | Completed | Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI | Dec 10, 2024 | ― |
| N,N-Dimethyltryptamine | Phase I | Healthy Volunteers | Completed | Clinical Study of DMT in Healthy Adults | Oct 06, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Biomind Labs Inc (TSE:BMND) have in its pipeline
Biomind Labs Inc TSE:BMND is currently developing the following drugs: Bmnd08, Brain Electrical Activity Monitor, Pharmacokinetic Study Of Sublingually Administered Psychoactive Substance, Biochemical Determinations, Acute Subjective Ratings Of Psychedelic Effects, Vital Signs, Cognitive Assessments, Psychiatric Assessments, Acute Subjective Ratings Of Psychedelic Effects, Vital Signs, Cognitive Assessments, Psychiatric Assessments, Sublingual Administration, Electroencephalography, Biochemical Mesurements, N,N-Dimethyltryptamine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
